ClinicalTrials.gg
Active, not recruitingNCT06892288Updated Aug 14, 2026

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

A Phase 2/3 interventional study of GLM101 (Part A, Double-blind) and Placebo (Part A, Double-blind) in Phosphomannomutase 2 Deficiency and PMM2-CDG, sponsored by Glycomine, Inc.. Active, not recruiting at 15 sites in 10 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Glycomine, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Ataxia with a site in United States — 18 open to participants now, 20 under way, 1 of them phase 3. Ataxia · United States.

Planned enrollment
12th of 42
50 · median 23
Started
2025
with 4 others
Phase 2/3
Only one
of the 63
Primary completion
2026-08
later than 2 of 19 live
Registered
56th of 63
by date

Among the 63 studies in Ataxia with a site in United States, this one is the 12th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 2 of the 19 other live ones, and was the 56th registered.

Ataxia

149 studies on the registry are indexed under Ataxia; 37 are open to participants now.

Browse Ataxia studies →

Open to participants now

18 of the 63 studies in Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Ataxia studies recruiting now, 13 (46%) set no upper age limit and 12 (43%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Ataxia with a site in United States, or all of them as a file.
02

Study summary

This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG.

The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).

Read the detailed description

This Phase 2b, multicenter, randomized, double-blind, placebo-controlled clinical study is designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric participants with PMM2-CDG. The study is structured into: a 4-week Screening Period, a 24-week Double-blind Treatment Period (Part A) to assess primary efficacy, a 24-week Open-label Extension Period (Part B), and a safety follow-up visit conducted 4 weeks after the last infusion. In Part A, participants will be randomly assigned to receive weekly intravenous infusions of either GLM101 at 30 mg/kg or a placebo for 24 weeks. After the end of Part A, participants will transition into Part B, a 24-week open-label extension where all participants will receive GLM101. The primary objective of the trial is to identify changes from baseline in coordination and muscle movement (ataxia) using the International Co-operative Ataxia Rating Scale (ICARS) after 24 weeks of taking GLM101 compared to a placebo in PMM2-CDG patients.

03

Conditions studied

  • Phosphomannomutase 2 Deficiency
  • PMM2-CDG

Browse trials for

Keywords

  • GLM101
  • CDG
  • CDG 1a
  • PMM2
  • Ataxia
  • GLM101-003
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria: Participant is eligible for participation in the study if all of the following apply:

  • Participant is aged ≥ 4 years old at the time of signing the consent.
  • Participant with molecular diagnosis of PMM2-CDG. Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of biallelic variants and PMM2 enzyme activity consistent with a diagnosis of PMM2-CDG. Diagnosis with laboratory report(s) on file is required.
  • Participant is willing and capable of completing the ICARS in its entirety without any assessment deemed as "not evaluable".
  • Participant screening total ICARS score is ≥ 20 and ≤ 80 .
  • Male or female participant has appropriate measures in place to prevent pregnancy:

    • If the participant is a woman of , i.e., fertile, following menarche and until becoming unless permanently sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy), she must not be pregnant (confirmed by a negative serum pregnancy test), is using a medically accepted method of (abstinence, a hormonal contraceptive associated with inhibition of ovulation in conjunction with a barrier method, or use of an intrauterine device), and must agree to continue using this method for 50 days after the last infusion. Note: sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception.
    • If the participant is a female of non-childbearing potential, she must be premenarchal, surgically sterile, or must have an ovarian dysfunction confirmed by a follicle stimulating hormone > 40 IU/ L (or higher per local institutional guidelines) and absence of menses for 12 months after last menstrual bleeding without an alternative medical cause.
    • If the participant is a sexually active male with female partners, the participant agrees to use a medically acceptable method of contraception (abstinence, the partner taking a hormonal contraceptive in conjunction with male participant using male condom, or use by the partner of an intrauterine device with a male participant using male condom) and agrees to continue using this method for 50 days after the last infusion.
  • If the participant is male, he must agree to refrain from donating sperm during the study and 50 days after the last infusion.
  • The participant is willing and able to provide /assent, directly or through his/her legally authorized representative.
  • The participant has a caregiver who is willing and able to complete questionnaires and provide informed consent.

Exclusion criteria: Participant will be excluded from participation in the study if any of the following criteria apply:

  • Has uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric or other significant disease based on the investigator judgment.
  • Diagnosis of congenital disorder of glycosylation (CDG) other than PMM2; Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of biallelic variants and the defined CDG enzyme activity consistent with a diagnosis of the CDG other than PMM2 CDG.
  • Has a history of liver transplant.
  • Has an active infection requiring parenteral antibiotics, antivirals, antifungals or treatment with systemic within 7 days prior to screening.
  • Has a history of drug or alcohol use disorder within 12 months prior to screening.
  • Has had a major surgical procedure within 30 days prior to screening or an upcoming planned major surgery.
  • Previous history of GLM101 administration.
  • Is currently participating in another interventional clinical study or has completed another clinical study with an drug or device within 30 days or 5 half-lives (whichever is longer) before enrollment.
  • Have consumed products or supplements containing mannose or biotin within 2 weeks prior to screening.
  • Elevated liver function tests: or AST > 3 × OR total > 2 × ULN or (INR) > 1.5 (if no anti-coagulation treatment) or INR > 4 (if participant on anti-coagulation treatment).
  • Has screening laboratory value(s) considered and not related to PMM2-CDG based on the investigator judgment.
  • Has serology positive for surface antigen or antibody during screening.
  • Has a by Fridericia (QTcF) ≥ 450 ms, or other abnormalities judged as clinically significant by the investigator.
  • Has history or presence, upon clinical evaluation, of any illness that might impact the safety of GLM101 infusion or evaluability of drug effect based on the investigator's and Sponsor's Medical Monitor's discretion.
  • Participant weighs above 120 kg.
  • Participant has a known or suspected to GLM101 or any components of the formulation used.
  • Any other reason for which, in the investigator's opinion, makes the participant unsuitable for study participation.
  • If female, must not be breastfeeding.
  • Estimated (eGFR) \<45 mL/min/ 1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for participants ≥ 18 years or Schwartz equation for participants \<18 years of age at screening.
  • Persons who have been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    GLM101- 30 mg/kg weekly administered IV in Part A (double-blind) and Part B (open-label)

    Drug: GLM101 (Part A, Double-blind) · Drug: GLM101 (Part B, Open-label)

  • Placebo comparator
    Placebo weekly admin. IV in Part A (double-blind); 30 mg/kg weekly admin. IV in Part B (open-label)

    Drug: Placebo (Part A, Double-blind) · Drug: GLM101 (Part B, Open-label)

Interventions

  • IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A

  • DrugPlacebo (Part A, Double-blind)

    IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A

  • IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants

06

What researchers measure

Primary outcomes

  1. Evaluation of Ataxia Changes Using the International Cooperative Ataxia Rating Scale (ICARS) in PMM2-CDG Patients at 24 weeks

    To characterize the change from Baseline in ataxia at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by ICARS. The scale is scored out of 100 with 19 items and four subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment (Part A).

    Time frame: At baseline and at week 24.

Secondary outcomes

  1. Evaluation of Change from Baseline in Gross Motor Function at 24 Weeks Using the Neuromuscular Gross Motor Outcome (GRO) in PMM2-CDG Patients

    To characterize the change from Baseline in gross motor function at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by GRO. The GRO is a gross neuromuscular motor outcome measure designed to assess whole body strength, motor development, and function for all levels of ability across the lifespan (Part A).

    Time frame: At baseline and at week 24.

  2. Evaluation of Change from Baseline in Ataxia at 24 Weeks Using the Scale for the Assess and Rating of Ataxia (SARA) in PMM2-CDG Patients

    To characterize the change from Baseline in ataxia at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by SARA. It consists of eight items of patient performance including gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, and heel-shin slide. It is scored out of 40 points with higher scores indicating higher levels of impairment (Part A).

    Time frame: At baseline and at week 24.

  3. Evaluation of Change in Global Impression of Improvement/Changes and Severity at 24 Weeks by PMM2-CDG Patients, Caregiver and Physician

    To evaluate the participant, caregiver, and physician global impression of improvement/change and severity at 24 weeks, comparing GLM101 to placebo (Part A).

    Time frame: At baseline and at week 24.

  4. Reporting of Adverse Events (AEs) in PMM2-CDG Patients at 24 weeks (Part A)

    Time frame: At baseline and up to week 24.

  5. Reporting of Blood Pressure in PMM2-CDG Patients at 24 weeks (Part A)

    Blood pressure will be measured in millimeters of mercury (mmHg).

    Time frame: At baseline and up to week 24.

  6. Reporting of Body Temperature in PMM2-CDG Patients at 24 weeks (Part A)

    Body Temperature will be measured in degree Celsius (°C).

    Time frame: At baseline and up to week 24.

  7. Reporting of Pulse Rate in PMM2-CDG Patients at 24 weeks (Part A)

    Pulse rate will be measured in beats per minute (bpm).

    Time frame: At baseline and up to week 24.

  8. Reporting of Respiratory Rate in PMM2-CDG Patients at 24 weeks (Part A)

    Respiratory rate will be measured in breaths per minute.

    Time frame: At baseline and up to week 24.

  9. Reporting of Cardiovascular Health Using Electrocardiogram (ECG) in PMM2-CDG Patients at 24 weeks (Part A)

    The following parameters will be evaluated: heart rate, PR, RR, QRS, QT intervals along with information on T and U-wave morphology.

    Time frame: At baseline and up to week 24.

  10. Evaluation of Ataxia Changes Using the International Cooperative Ataxia Rating Scale (ICARS) in PMM2-CDG Patients from baseline to the End of the Study

    To evaluate the effect of GLM101 on changes in ICARS score to the end of study. The objective is to evaluate ICARS changes over 48 weeks, comparing early versus delayed GLM101 treatment, placebo-to-GLM101 transitions, and visit-wise changes in participants receiving GLM101 (Part B).

    Time frame: At baseline and at weeks 24 and 48.

  11. Evaluation of Changes in the Neuromuscular Gross Motor Outcome (GRO) Score in PMM2-CDG Patients from baseline to the End of the Study

    To evaluate the effect of GLM101 on changes in GRO score to the end of study. The objective is to evaluate changes in GRO score over 48 weeks, comparing early versus delayed GLM101 treatment, placebo-to-GLM101 transitions, and visit-wise changes in participants receiving GLM101 (Part B).

    Time frame: At baseline and at weeks 24 and 48.

  12. Evaluation of Changes in the Scale for the Assess and Rating of Ataxia (SARA) Score in PMM2-CDG Patients from baseline to the End of the Study

    To evaluate the effect of GLM101 on change in SARA score to the end of study. The objective is to evaluate changes in SARA Score over 48 weeks, comparing early versus delayed GLM101 treatment, placebo-to-GLM101 transitions, and visit-wise changes in participants receiving GLM101 (Part B).

    Time frame: At baseline and at weeks 24 and 48.

  13. Evaluation of Change in Global Impression of Improvement/Changes and Severity from baseline to the End of the Study by PMM2-CDG Patients, Caregiver and Physician

    To evaluate the participant, caregiver, and physician global impression of improvement/change and severity up to 48 weeks of dosing with GLM101. Evaluation of visit-wise changes in participant, caregiver, and clinician impressions of change, severity, and improvement for overall, ataxia, and gross motor function (Part B).

    Time frame: At baseline and up to week 48.

  14. Reporting of Adverse Events in PMM2-CDG Patients from Baseline to the End of the Study (Part B)

    Time frame: At baseline and up to week 48.

  15. Reporting of Blood Pressure in PMM2-CDG Patients from Baseline to the End of the Study (Part B)

    Blood pressure will be measured in millimeters of mercury (mmHg).

    Time frame: At baseline and up to week 48.

  16. Reporting of Pulse Rate in PMM2-CDG Patients from Baseline to the End of the Study (Part B)

    Pulse rate will be measured in beats per minute (bpm).

    Time frame: At baseline and up to week 48.

  17. Reporting of Body Temperature in PMM2-CDG Patients from Baseline to the End of the Study (Part B)

    Body Temperature will be measured in degree Celsius (°C).

    Time frame: At baseline and up to week 48.

  18. Reporting of Respiratory Rate in PMM2-CDG Patients from Baseline to the End of the Study (Part B)

    Respiratory rate will be measured in breaths per minute.

    Time frame: At baseline and up to week 48.

  19. Reporting of Cardiovascular Health Changes Using Electrocardiogram (ECG) in PMM2-CDG Patients from Baseline to the End of the Study (Part B)

    The following parameters will be evaluated: heart rate, PR, RR, QRS, QT intervals along with information on T and U-wave morphology.

    Time frame: At baseline and up to week 48.

  20. Maximum Concentration (Cmax) of Mannose-1-phosphate (M1P) in PMM2-CDG Patients as Key PK Parameter over 48 weeks to the End of the Study (Part B)

    Cmax will be estimated using Blood Samples collected Pre- and Post-Infusion.

    Time frame: At Baseline and at weeks 11, 12, 20, 21, 35, 36, 44, 45.

  21. Time from dosing to the Maximum Concentration (tmax) of Mannose-1-phosphate (M1P) in PMM2-CDG Patients as Key PK Parameter over 48 weeks to the End of the Study (Part B)

    tmax will be estimated using Blood Samples collected Pre- and Post-Infusion.

    Time frame: At Baseline and at weeks 11, 12, 20, 21, 35, 36, 44, 45.

  22. Area under the concentration versus time curve (AUC) of Mannose-1-phosphate (M1P) in PMM2-CDG Patients as Key PK Parameter over 48 weeks to the End of the Study (Part B)

    AUC will be estimated using Blood Samples collected Pre- and Post-Infusion.

    Time frame: At Baseline and at weeks 11, 12, 20, 21, 35, 36, 44, 45.

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Aug 2026, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Mar 24, 2025
StartActual
Jul 9, 2025
Primary completionActual
Aug 5, 2026
CompletionEst.
Apr 30, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06892288
Lead sponsor
Glycomine, Inc.
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jul 9, 2025
Primary completion
Aug 5, 2026
Completion
Apr 30, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Chief Medical Officer
study director · Glycomine, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLM101

Start the discussion